Publications by authors named "David Rizzieri"

100Publications

Clinical and Neuroimaging Correlates of Post-Transplant Delirium.

Biol Blood Marrow Transplant 2020 Dec 19;26(12):2323-2328. Epub 2020 Sep 19.

Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.09.016DOI Listing
December 2020

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

Blood Adv 2020 Jul;4(13):3180-3190

Center for International Blood and Marrow Transplant Research, Department of Medicine, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362362PMC
July 2020

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Curr Hematol Malig Rep 2019 12;14(6):515-522

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00556-2DOI Listing
December 2019

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Haematologica 2020 05 26;105(5):1329-1338. Epub 2019 Sep 26.

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.220756DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193485PMC
May 2020

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

N Engl J Med 2019 04;380(17):1628-1637

From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815105DOI Listing
April 2019

Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome.

Clin Cancer Res 2019 07 5;25(13):4155-4167. Epub 2019 Apr 5.

Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800136PMC
July 2019

Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 10 29;18(10):679-686. Epub 2018 Jul 29.

Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.07.285DOI Listing
October 2018

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.

Adv Radiat Oncol 2016 Oct-Dec;1(4):272-280. Epub 2016 Jul 15.

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2016.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514157PMC
July 2016

Treatment of blastic plasmacytoid dendritic cell neoplasm.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):16-23

Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142460PMC
December 2016

CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.

Cancer Cell 2016 Nov 27;30(5):792-805. Epub 2016 Oct 27.

Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137811PMC
November 2016

Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

Authors:
David Rizzieri

Crit Rev Oncol Hematol 2016 Sep 16;105:5-17. Epub 2016 Jul 16.

Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, 20 Duke Medicine Circle, Durham NC 27710, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.07.008DOI Listing
September 2016

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.

Eur J Haematol 2016 Oct 31;97(4):313-20. Epub 2016 May 31.

Division of Hematologic Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12771DOI Listing
October 2016

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

J Clin Oncol 2016 06 4;34(16):1864-71. Epub 2016 Apr 4.

Brian C. Shaffer and Martin Tallman, Memorial Sloan Kettering Cancer Center; Adriana K. Malone, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; Ran Reshef, Columbia University Medical Center, New York; Mark Litzow, Mayo Clinic Rochester; Jane Liesveld, University of Rochester Medical Center, Rochester; Peter H. Wiernik, Our Lady of Mercy Medical Center, Bronx, NY; Kwang Woo Ahn, Zhen-Huan Hu, and Wael Saber, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Taiga Nishihori and Mohamed A. Kharfan-Dabaja, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David Valcárcel, Hospital Vall d'Hebron, Barcelona, Spain; Michael R. Grunwald, Omotayo Fasan, and Edward Copelan, Levine Cancer Institute, Carolinas HealthCare System, Charlotte; William Allen Wood, University of North Carolina at Chapel Hill, Chapel Hill; David A. Rizzieri, Duke University Medical Center, Durham, NC; Ulrike Bacher, University of Medicine Göttingen, Göttingen, Germany; Betty Hamilton and Aaron Gerds, Cleveland Clinic Taussig Cancer Institute; Matt Kalaycio and Ron Sobecks, Cleveland Clinic Foundation, Cleveland; Basem William, Ohio State University Medical Center, Columbus, OH; Ayman Saad and Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Corey Cutler and Edwin Alyea, Dana-Farber Cancer Institute, Boston, MA; Erica Warlick and Celalettin Ustun, University of Minnesota Medical Center, Minneapolis, MN; Baldeep Mona Wirk, Seattle Cancer Care Alliance, Seattle, WA; Mitchell Sabloff, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario; Andrew Daly, Tom Baker Cancer Center, Calgary, Alberta, Canada; David Marks, University Hospitals Bristol National Health Service Trust, Bristol; Robert Peter Gale, Imperial College London, London, United Kingdom; Richard Olsson, Karolinska Institutet, Stockholm, Sweden; Alan M. Miller, Baylor University Medical Center; Rammurti Kamble

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966345PMC
June 2016

Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.

Adv Hematol 2016 2;2016:1423493. Epub 2016 Feb 2.

Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/1423493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754478PMC
March 2016

Immunotherapeutic applications of NK cells.

Pharmaceuticals (Basel) 2015 May 25;8(2):250-6. Epub 2015 May 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph8020250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491659PMC
May 2015

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

J Clin Oncol 2015 Apr 2;33(11):1252-7. Epub 2015 Mar 2.

Richard M. Stone, Emanuele Mazzola, and Donna Neuberg, Dana-Farber Cancer Institute, Boston; Ante S. Lundberg, Antisoma, Cambridge, MA; Steven L. Allen, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success; Meir Wetzler, Roswell Park Cancer Institute, Buffalo; Martin S. Tallman, Memorial Sloan Kettering Cancer Center, New York, NY; Arnaud Pigneux, Hopital Haut-Leveque, Pessac, France; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; David Rizzieri, Duke University Medical Center, Durham; Bayard Powell, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC; Harry P. Erba, University of Michigan Health System, Ann Arbor, MI; Lloyd Damon, University of California San Francisco, San Francisco, CA; Jun-Ho Jang, Samsung Medical Center, Seoul, Korea; Krzysztof Warzocha, Institute of Hematology and Transfusiology, Warsaw, Poland; Támas Masszi, Szent Istvan and Szent Laszlo Corporate Hospital, Budapest; Miklos Egyed, Kaposi Mor County Teaching Hospital, Kasposvar, Hungary; Mikkael A. Sekeres, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Heinz-August Horst, Universitatsklinikum Schleswig-Holstein, Kiel, Germany; Dominik Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Scott R. Solomon, Blood and Marrow Transplant Program and Northside Hospital, Atlanta, GA; and Parameswaran Venugopal, Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/26/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.0952
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.0952DOI Listing
April 2015

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Ther Adv Hematol 2014 Dec;5(6):211-20

Duke University Medical Center - Medicine, 1149 North Pavilion Duke University Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620714552615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250268PMC
December 2014

Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000/µl.

J Clin Apher 2015 Feb 28;30(1):28-31. Epub 2014 Jun 28.

Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jca.21343DOI Listing
February 2015

Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.

Nat Genet 2014 Mar 2;46(3):245-52. Epub 2014 Feb 2.

1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3] Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA. [4] Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267534PMC
March 2014

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

J Clin Oncol 2014 Feb 16;32(4):273-81. Epub 2013 Dec 16.

Timothy S. Fenske and Mehdi Hamadani, Medical College of Wisconsin; Mei-Jie Zhang, Jeanette Carreras, and Parameswaran N. Hari, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Ernesto Ayala, H. Lee Moffitt Cancer Center and Research Institute, Tampa; Baldeep M. Wirk, Shands Healthcare and University of Florida, Gainesville, FL; Linda J. Burns, University of Minnesota Medical Center, Fairview, Minneapolis; David J. Inwards, Mayo Clinic Rochester, Rochester, MN; Amanda Cashen, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO; Luciano J. Costa, Medical University of South Carolina, Charleston, SC; César O. Freytes, South Texas Veterans Health Care System and University of Texas Health Science Center, San Antonio, TX; Robert P. Gale, Imperial College; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Leona A. Holmberg and David G. Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA; Hillard M. Lazarus, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Reinhold Munker, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA; Miguel-Angel Perales, Memorial Sloan-Kettering Cancer Center, New York, NY; David A. Rizzieri, Duke University Medical Center, Durham, NC; Harry C. Schouten, Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; Sonali M. Smith, University of Chicago Hospitals, Chicago, IL; Edmund K. Waller, Emory University Hospital, Atlanta, GA; and Ginna G. Laport, Stanford Hospital and Clinics, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897255PMC
February 2014

Is timing everything?

Authors:
David Rizzieri

Biol Blood Marrow Transplant 2014 Feb 14;20(2):145-6. Epub 2013 Dec 14.

Duke University Medical Center, Durham, North Carolina. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.12.556DOI Listing
February 2014

New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.

Int J Hematol Oncol 2013 Feb;2(1)

Division of Hematologic Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh.13.4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841006PMC
February 2013

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Biol Blood Marrow Transplant 2014 Feb 20;20(2):257-63. Epub 2013 Nov 20.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140655PMC
February 2014

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

J Clin Oncol 2013 Nov 14;31(33):4199-206. Epub 2013 Oct 14.

Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego; John M. Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.48.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.3685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878008PMC
November 2013

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Proc Natl Acad Sci U S A 2013 Jun 4;110(25):E2298-307. Epub 2013 Jun 4.

Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore 169857.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1301838110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3690864PMC
June 2013

Individualizing treatment decisions for older adults with hematologic malignancies.

Am Soc Clin Oncol Educ Book 2013 :208-19

From the Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Department of Medicine, Division of Hematologic Malignancies and Cell Therapy, Duke University Medical Center, Durham, NC; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy; Department I of Internal Medicine and Center of Integrated Oncology Köln Bonn, University of Cologne, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2013.33.208DOI Listing
April 2016

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

Lancet Oncol 2013 Apr 28;14(4):354-62. Epub 2013 Feb 28.

Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70037-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557006PMC
April 2013

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Proc Natl Acad Sci U S A 2013 Feb 16;110(6):2300-5. Epub 2013 Jan 16.

Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1206551110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568344PMC
February 2013

MDS: unraveling the mystery.

Authors:
David A Rizzieri

Blood 2012 Dec;120(25):4906-8

Duke Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-09-452755DOI Listing
December 2012

Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria.

Clin Adv Hematol Oncol 2012 Feb;10(2):136-7

Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
February 2012